Kang Yuan Pharmaceutical: Obtained the Notice of Approval for Clinical Trials of Yunspleen-Phlegm Dissolving Granules

Kangyuan Pharmaceutical announced on January 26th that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Yunpi Huatan Tongqiao Granules. The main function of this medicine is to regulate the spleen, transform phlegm, and open the meridians, and it is used for children with adenoid hypertrophy and spleen deficiency phlegm obstruction syndrome. Currently, the main chemical drugs used to treat children with adenoid hypertrophy include nasal corticosteroids, leukotriene receptor antagonists, antihistamines, and immune modulators. There are no approved traditional Chinese medicines on the market for this condition yet. The successful market approval of this product will help fill a clinical gap and has high clinical value.